همایش ملی بیوانفورماتیک ایران

صفحه اصلی / 4th international edition and 13th Iranian Conference on Bioinformatics

Exploring the interaction between hsa-miR-122-5p and CDC25A gene in Breast carcinoma progression via computational analysis

نویسندگان :

Sara Seyed Shazileh¹

1- فرد

کلمات کلیدی :

CDC25A،breast carcinoma،hsa-miR-122-5p

چکیده :

Introduction: The most prevalent type of cancer among women is breast carcinoma. An estimated 2.3 million new breast carcinoma cases are diagnosed annually around the world. Numerous risk factors, such as age, genetic predisposition, hormonal factors, and lifestyle, have been identified, although the precise cause is still unknown. Depending on the unique features of the tumor and the patient, treatment strategies usually combine hormone therapy, chemotherapy, radiation therapy, surgery, and, more recently, immunotherapy. Therefore, in order to find potential therapeutic targets and BC biomarkers, it is essential to clarify the molecular pathways underlying the onset and spread of breast carcinoma. The cell cycle can be regulated by members of the CDC25 family. By preventing the phosphorylation of cyclin-dependent kinases (CDKs), CDC25 regulates the progression of the cell cycle and activates the CDK complexes. Several cancer types have been shown to express CDC25A at high levels, and overexpression of CDC25A is associated with a poor prognosis in about 50% of BC cases. By targeting CDC25A, we anticipate that hsa-miR-122-5p may be able to increase the radiosensitivity of breast cancer cells and impede the spread of the disease. CDC25A's regulatory mechanism in BC hasn't been thoroughly investigated, though. MATERIALS AND METHODS: Advances in high-throughput profiling methods and the availability of public data sets such as The Cancer Genome Atlas Program (TCGA) have allowed for the profiling of a large number of coding transcripts and the mapping of their underlying mechanisms of action. Many different processes in cell biology are regulated by miRNAs. In addition to helping to suppress these pathways, obtaining the miRNA target genes can advance knowledge of gene therapy and cancer regulation. Using the mirwalk database, we predicted gene expression patterns and assessed TCGA RNA-seq data following miRNA target gene prediction in this endeavor. RESULTS AND DISCUSSION: Hsa-miR-122-5p targets CDC25A, which has a high score, according to the results. Additionally, the TCGA data analysis showed that the tissue from breast carcinomas had a markedly elevated expression of this gene. CONCLUSION: It is predicted that in breast cancer, downregulating hsa-miR-122-5p expression leads to upregulating CDC25A expression. Furthermore, in addition to acting as a biomarker for breast carcinoma, upregulation of CDC25A expression is anticipated to aid in the disease's progression.